Healthcare can be complicated.
Your cardiology news shouldn’t be.
Join thousands of cardiology leaders today.
Atrial Fibrillation September 12, 2024
AFib Might Be Far More Common Than We Think September 12, 2024
A JACC study suggests that atrial fibrillation is far more prevalent than many previously thought, estimating that nearly one in 20 American adults have been diagnosed with the disease. UCSF researchers analyzed medical records from 29M adults who received hospital-based care in California from 2005 to 2019 (51yr avg. age, 54% women, 50% White), finding […]
Pharmaceuticals September 9, 2024
Questioning Beta-Blocker Interruption After Heart Attack September 9, 2024
Results from the ABYSS trial surprised many at ESC 2024, finding that patients who continue beta-blocker therapy after heart attacks have better long-term outcomes than patients who stop taking the drugs, and they don’t experience the quality of life downsides that some might expect.
Atrial Fibrillation September 5, 2024
Burn the Ships? What OCEANIC-AF Means for Asundexian and Factor XI September 5, 2024
Nearly a year after Bayer halted its OCEANIC-AF trial, the study’s ESC 2024 presentation revealed new insights into asundexian’s AFib stroke-prevention challenges and what they might mean for Factor XI inhibitors.
Pharmaceuticals September 3, 2024
Alylam’s Vutrisiran Shines in HELIOS-B Trial September 3, 2024
Alylam’s vutrisiran dominated early ESC 2024 headlines and conversations, after full results from the Phase 3 HELIOS-B trial highlighted its significant impact on transthyretin amyloidosis with cardiomyopathy (ATTR-CM).
More Stories
Cholesterol Reduction August 29, 2024
Novartis Leqvio’s Case for Broader ASCVD Prevention August 29, 2024
Novartis’ Leqvio took a major step towards establishing itself as an LDL-C monotherapy, after topline results from the V-MONO study revealed significant LDL-C reductions in patients with low or moderate ASCVD risks.
Preventive Cardiology August 26, 2024
Tirzepatide’s Prediabetes and Hypertension Impact August 26, 2024
It looks like we might be able to add prediabetes and hypertension to the growing list of conditions that Eli Lilly’s “weight loss drug” tirzepatide is able to treat, after new analysis of the SURMOUNT-1 trial showed significant reductions in blood pressure and diabetes progression.
Cardiology Business August 22, 2024
J&J Expands Into Interventional HF Treatments With V-Wave Acquisition August 22, 2024
Johnson & Johnson expanded deeper into heart failure and interventional cardiology this week, acquiring interatrial shunt-maker V-Wave for $600M upfront and up to $1.7B with certain milestones.
Pharmaceuticals August 19, 2024
Medicare Drug Cuts Target CVD Meds, Drive Debates August 19, 2024
The White House finally unveiled its negotiated Medicare drug prices, bringing 38%-76% reductions to the first 10 drugs, while drawing mixed industry reactions.
Heart Failure August 15, 2024
Rivus HU6 Shows Obesity-HFpEF Potential August 15, 2024
Rivus Pharmaceuticals’ HU6 is showing promise as a future obesity-related HFpEF treatment, after topline results from its Phase 2a HuMAIN trial revealed valuable weight, symptom, and cardiometabolic improvements - without the risk of muscle loss.
Artificial Intelligence August 12, 2024
Cardiology AI Clearances Growing, Diversifying August 12, 2024
The FDA updated its healthcare AI database last week, increasing its list of AI-enabled clearances to a whopping 950 medical devices, while highlighting some interesting trends in cardiovascular AI.
Heart Failure August 8, 2024
Bayer’s Kerendia Could Become First nsMRA Heart Failure Treatment August 8, 2024
Bayer’s nsMRA finerenone (Kerendia) might be on track to becoming a key heart failure treatment, after topline results from the FINEARTS-HF trial showed that finerenone significantly reduces cardiovascular death and HF events among patients with mildly reduced or preserved ejection fraction.
Heart Failure August 5, 2024
Tirzepatide Improves HFpEF Symptoms and Outcomes August 5, 2024
Lilly’s blockbuster GLP-1 tirzepatide appears poised to become the next major HFpEF drug, after topline results from the SUMMIT trial showed that it significantly improved both outcomes and symptoms among patients with heart failure with preserved ejection fraction and obesity.
Pharmaceuticals August 1, 2024
NewAmsterdam’s Obicetrapib Slashes HeFH LDL-C in First Phase 3 Trial August 1, 2024
Topline results are in from NewAmsterdam Pharma’s BROOKLYN study, showing that obicetrapib safely and effectively reduces LDL cholesterol in patients with heterozygous familial hypercholesterolemia who can’t be effectively treated by current cholesterol drugs.
Cardiology Business July 29, 2024
Edwards Acquires JenaValve and Endotronix, Expands into Aortic Regurgitation and Heart Failure July 29, 2024
Edwards Lifesciences is going all-in on structural heart and heart failure, acquiring aortic valve-maker JenaValve Technology and implantable heart failure monitor company Endotronix for $1.2B and up to $445M in milestone payments.
Surgeries & Interventions July 25, 2024
Magenta Medical Adds $105M, Targets MCS Disruption July 25, 2024
Israeli heart pump startup Magenta Medical wrapped up a $105M financing round to advance clinical programs supporting its Elevate left ventricular assist device, a percutaneous heart pump that Magenta believes could disrupt the mechanical circulatory support segment.
Patient Engagement July 22, 2024
The Psychological Impact of AFib Wearables July 22, 2024
AFib patients are increasingly using consumer wearable devices for symptom monitoring, but a new JAHA study suggests that these devices' often-publicized healthcare benefits are offset by their negative impacts on patient anxiety and healthcare overuse.
Pharmaceuticals July 18, 2024
Lexeo LX2006 Shows Promise for Friedreich’s Ataxia Cardiomyopathy July 18, 2024
Lexeo Therapeutics gave the 5,000 Americans with Friedreich’s ataxia cardiomyopathy reason for optimism, publishing early results that suggest its LX2006 gene therapy could be able to treat FA cardiomyopathy.
Surgeries & Interventions July 15, 2024
Baylor St. Luke’s Settles Concurrent Cardiac Surgery Case July 15, 2024
Cardiac surgeon compensation is generally a numbers game - the more procedures you do, the more you make. However, a Medicare fraud settlement featuring some of Houston’s most prominent institutions and cardiac surgeons reveals the pitfalls of this incentive structure.
Population Health July 11, 2024
Nearly Half of American Counties Don’t Have Cardiologists July 11, 2024
A new JACC study found that 46.3% of U.S. counties don’t have a single cardiologist, meaning that the 22M people who live in these "cardiology desert" countries have to drive an average of 90 miles round trip to see their cardiologist.
Structural Heart July 8, 2024
Older Patients and Asymptomatic Valvular Heart Disease July 8, 2024
A new study out of the UK found that over a quarter of people aged 60+ have asymptomatic valvular heart disease, and revealed that prevalence increases as patients age -- potentially providing new reasons to screen older patients for VHD.
Cardiology July 1, 2024
Cardiology in H1 2024 July 1, 2024
The first half of 2024 is now a wrap, and it was another big one in cardiology. Here are some of Cardiac Wire’s top six storylines from the last six months, plus some things to keep in mind as we head into 2024’s second half.
Surgeries & Interventions June 27, 2024
Shockwave Therapy’s Ischemic Heart Failure Potential June 27, 2024
New research out of Austria suggests that cardiac shockwave therapy could help address ischemic heart failure patients’ myocardial regeneration challenges, allowing meaningful LVEF and quality of life improvements, and potentially better outcomes.
